Glucagon-like peptide-1 receptor (GLP-1R) agonists may potentially exert neuroprotective effects against nervous system diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The gene discussed is GLP1R; the disease is early-onset autosomal dominant Alzheimer disease.